Выбор темы
Выбор стиля шрифта
Johnson & Johnson новости
04/05
💡
МНЕНИЕ: Johnson & Johnson получила выгоду от IPO Kenvue - Синара
25/04
Johnson & Johnson планирует IPO своего подразделения по выпуску медицинских товаров на $40 млрд: размещение станет крупнейшим в 2023 году.
24/04
💡
МНЕНИЕ: Успех IPO подразделения Kenvue вызывает некоторые сомнения - Синара
19/04
💡
МНЕНИЕ: В краткосрочной перспективе ожидается восстановление стоимости акций Johnson & Johnson - Синара
31/01
💡
МНЕНИЕ: Johnson & Johnson не удастся отделаться от исков - Синара
20/07
💡
МНЕНИЕ: Давление на прибыль Johnson & Johnson в 2022 году из-за инфляции и логистических проблем - Синара
15/06
JNJ - Сделка Инсайдера: продажа 10 июня 2022
01/06
JNJ - Сделка Инсайдера: продажа 26 мая 2022
26/04
JNJ - Сделка Инсайдера: продажа 21 апреля 2022
20/04
💡
МНЕНИЕ: Johnson & Johnson: нейтральная отчетность и повышение дивидендов - Синара
22/03
JNJ - Сделка Инсайдера: продажа 17 марта 2022
18/03
JNJ - Сделка Инсайдера: продажа 15 марта 2022
28/02
💡
МНЕНИЕ: У Johnson & Johnson вероятность выплат по судебным искам снижается - Синара
03/02
🔗
The Motley Fool: Here's What to Like About Johnson & Johnson's Q4 Update
02/02
🔗
Benzinga: Johnson & Johnson, Distributors Reach $590M Opioid Settlement For Tribe Claims: Report
02/02
🔗
GuruFocus: A Trio of High-Yield Stocks for Dividend Investors
01/02
🔗
CNBC Television: What are the best dividend plays? #AskHalftime
01/02
🔗
Reuters: Drug distributors, J&J to pay $590 million to settle U.S. tribes' opioid claims
27/01
🔗
Reuters: Drugmaker Galapagos names former J&J exec Paul Stoffels as CEO
26/01
🔗
MarketBeat: Is It Time To Buy The Rebound In Johnson & Johnson?
26/01
🔗
CNN Business: Johnson & Johnson expects its Covid vaccine sales to surge -- but still lag its rivals
25/01
🔗
PYMNTS: Johnson & Johnson Readies to Spin Off Business Units As COVID Effects Linger in 2022
25/01
🔗
Seeking Alpha: Johnson & Johnson (JNJ) CEO Joaquin Duato on Q4 2021 Results - Earnings Call Transcript
25/01
🔗
Zacks Investment Research: J&J (JNJ) Q4 Earnings Beat Estimates by a Penny, Sales Miss
25/01
💡
МНЕНИЕ: Перспективы Johnson & Johnson улучшаются - Финам
25/01
🔗
Invezz: J&J CFO on Q4 results: ‘we're very well positioned for 2022'
25/01
🔗
Zacks Investment Research: Johnson & Johnson (JNJ) Surpasses Q4 Earnings Estimates
25/01
🔗
CNBC Television: Johnson & Johnson CFO breaks down mixed earnings report, full-year guidance
25/01
🔗
Benzinga: Johnson & Johnson's FY21 COVID-19 Vaccine Sales Below Expectations
25/01
🔗
Market Watch: J&J shares down 1.3% premarket after Q4 revenue lags consensus
25/01
🔗
Seeking Alpha: Johnson & Johnson: The Right Prescription For A Turbulent Market
24/01
🔗
Benzinga: Pfizer, AstraZeneca or J&J COVID-19 Shots Boost Sinovac Regime, Brazilian Study Shows
24/01
🔗
Seeking Alpha: Johnson & Johnson Stock: Spinning Off Its Litigations And Bankruptcy
24/01
🔗
Seeking Alpha: Johnson & Johnson: It's Not A Matter Of If But When To Add This Stock
21/01
🔗
Zacks Investment Research: J&J (JNJ) to Set the Stage for Pharma Sector Q4 Earnings
21/01
🔗
The Motley Fool: 2 Dividend Stocks to Buy and Hold Forever
21/01
🔗
Forbes: Will Johnson & Johnson Stock Rise After Q4 Results?
19/01
🔗
Market Watch: Earnings Outlook: What's next for a J&J that will soon be split into two different companies
15/01
🔗
Reuters: J&J reaches opioid settlement with holdout state New Mexico
14/01
🔗
Zacks Investment Research: Q4 Earnings Update and Analyst Reports for Apple, JNJ & McDonald's
14/01
🔗
Benzinga: Johnson and Johnson' COVID-19 Booster Is 85% Effective Against Omicron Hospitalization, South African Study Shows
13/01
🔗
The Motley Fool: 3 Reasons to Buy This Newly Minted Dividend King
11/01
🔗
PYMNTS: Johnson & Johnson-Microsoft Pact Shows Transformative Potential of Connected Healthcare
10/01
🔗
Seeking Alpha: Johnson & Johnson (JNJ) CEO Joaquin Duato at JPMorgan 40th Annual Healthcare Conference (Transcript)
08/01
🔗
The Dog of Wall Street: Johnson & Johnson To Spin Off Its Consumer Division and Focus On Pharmaceuticals
05/01
🔗
Reuters: Nevada to join $26 billion opioid settlement with J&J, drug distributors
31/12
🔗
Zacks Investment Research: J&J (JNJ) COVID Booster Jab Shows Effectiveness Against Omicron
31/12
🔗
Pulse2: Johnson & Johnson Stock (JNJ): Why The Price Increased
31/12
🔗
Zacks Investment Research: J&J (JNJ) Seeks FDA Approval for Myeloma Drug Teclistamab
30/12
🔗
Barrons: J&J Booster Cuts Hospitalizations Linked to Omicron: Study
30/12
🔗
Market Watch: J&J's COVID-19 vaccine booster was 85% effective against hospitalization, in South Africa study
29/12
🔗
The Motley Fool: Invest Like Warren Buffett in 2022 and Buy These 3 Stocks for the Long Haul
28/12
🔗
Seeking Alpha: Johnson & Johnson: Time To Load Up Before The Split
27/12
🔗
The Motley Fool: Johnson & Johnson Stock: Bull vs. Bear
23/12
🔗
Seeking Alpha: Johnson & Johnson: Another 2022 Safety Bet
21/12
🔗
The Motley Fool: What Are the Best Vaccine Stocks to Own in 2022?
21/12
🔗
Zacks Investment Research: Johnson & Johnson (JNJ) Stock Moves -0.29%: What You Should Know
17/12
🔗
CNBC: CDC Director Dr. Walensky says any vaccine is better than none in recommending J&J's Covid shots
17/12
🔗
Benzinga: Johnson & Johnson's, Sputnik, Sinopharm COVID-19 Vaccines Show Weakness Against Omicron Variant: Study
17/12
🔗
Forbes: Johnson & Johnson Stock Is Likely To See Higher Levels In The Near Term
17/12
🔗
Pulse2: Johnson & Johnson Stock (JNJ): $161 Price Target From Goldman Sachs
17/12
🔗
CNBC Television: CDC panel recommends preference for mRNA vaccines over J&J
16/12
🔗
The Motley Fool: Unstoppable Dividend King for 2022: AbbVie or Johnson & Johnson?
16/12
🔗
Zacks Investment Research: J&J's (JNJ) COVID-19 Booster Jab Gets CHMP Recommendation
15/12
🔗
Benzinga: European Medicines Committee Backs Johnson & Johnson's COVID-19 Booster Dose
13/12
🔗
Benzinga: Comparing Data: Sanofi Vs. Johnson & Johnson Multiple Myeloma Therapies In Newly Diagnosed Patients
10/12
🔗
InvestorPlace: 3 Healthcare Stocks for Long-Term Dividend Growth
10/12
🔗
PRNewsWire: Johnson & Johnson to Host Investor Conference Call on Fourth-Quarter Results
10/12
🔗
Zacks Investment Research: J&J's (JNJ) COVID-19 Booster Jab Gets WHO Recommendation
10/12
JNJ - Сделка Инсайдера: продажа 07 декабря 2021
10/12
JNJ - Сделка Инсайдера: продажа 07 декабря 2021
06/12
🔗
Benzinga: Johnson & Johnson Booster COVID-19 Shot Shows Encouraging Action After Pfizer/BioNTech Jab
06/12
🔗
Pulse2: Johnson & Johnson Stock (JNJ): $200 Price Target Reiterated By Credit Suisse
05/12
🔗
GuruFocus: J&J, Pfizer, Novartis Among Pharma Giants With Biggest War Chests
03/12
🔗
CNBC Television: FDA prepares for rapid review of omicron vaccines and drugs: WSJ
02/12
🔗
Zacks Investment Research: Johnson & Johnson (JNJ) Gains As Market Dips: What You Should Know
01/12
🔗
Stockmarketcom: 5 Biotech Stocks For Your December 2021 Watchlist
30/11
🔗
Zacks Investment Research: J&J (JNJ) to Explore Omicron Version of its COVID Vaccine
29/11
🔗
Seeking Alpha: Is Johnson & Johnson Split Into Two Companies Good For Stock Investors?
29/11
🔗
24/7 Wall Street: 5 Dividend Stocks Could Be Big Winners After the New COVID-19 Variant Shock
26/11
🔗
CNBC Television: Dr. Gottlieb: The vaccines might be sufficient to control spread of new Covid variant
26/11
🔗
The Motley Fool: Better Buy: Johnson & Johnson or All 30 Dow Jones Stocks?
15/11
МНЕНИЕ: Планы по разделу Johnson&Johnson могут благоприятно отразиться на темпах роста выручки в будущем - Фридом Финанс
19/10
МНЕНИЕ: Johnson & Johnson отчиталась о росте выручки и прибыли - Финам
18/10
МНЕНИЕ: Johnson & Johnson представит отчет за 3 квартал - Финам
07/09
Morgan Stanley снижает рекомендации по акциям Johnson & Johnson, Merck, и Amgen
25/08
Johnson & Johnson сообщила, что бустерная вакцина увеличивает выработку антител в 9 раз
21/07
Реакция инвесторов на финансовые результаты Johnson & Johnson за 2 квартал 2021 года неоднозначна - Финам
21/07
Чистая прибыль Johnson & Johnson во втором квартале выросла на 73%
20/07
Чистая прибыль Johnson & Johnson может вырасти за 2 квартал 2021 года на 37% - Финам
Загрузить еще